Amid the declining clinical severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and diminishing public uptake of annual coronavirus disease 2019 (Covid-19) vaccines, ...
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...
RNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production.
The updated 2024-2025 mRNA COVID-19 vaccine was linked to moderate protection against severe COVID-19 outcomes, including hospitalizations.
The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...
The cb1 vaccine platform demonstrates a single, intranasally administered vaccine can confer wide-ranging immunity that may protect against both current and future beta-coronavirus spillovers, ...
CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for ...
Morning Overview on MSN
Scientists are about to unleash the 1st ever universal vaccine
Stanford Medicine researchers reported this week that an intranasal vaccine formula protected mice against a striking range of respiratory threats, from SARS-CoV-2 to bacterial infections, in what ...
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results